Special Issue "Adenoviral Vectors"
Deadline for manuscript submissions: 31 July 2014
Dr. David T. Curiel
Washington University School of Medicine, Department of Radiation Oncology, 4511 Forest Park, St. Louis, MO 63108, USA
Phone: +1 314 362 9789
Fax: +1 314 362 9797
Interests: adenovirus; virotherapy; gene therapy
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed Open Access monthly journal published by MDPI.
Review: Peptide-Based Technologies to Alter Adenoviral Vector Tropism: Ways and Means for Systemic Treatment of Cancer
Viruses 2014, 6(4), 1540-1563; doi:10.3390/v6041540
Received: 10 February 2014; in revised form: 15 March 2014 / Accepted: 20 March 2014 / Published: 2 April 2014| Cited by 1 | PDF Full-text (647 KB) | HTML Full-text | XML Full-text
Viruses 2014, 6(2), 832-855; doi:10.3390/v6020832
Received: 18 December 2013; in revised form: 10 February 2014 / Accepted: 11 February 2014 / Published: 17 February 2014| PDF Full-text (933 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Article
Title: Effective Transfer of the Oncolytic Adenoviral Vector Delta24-RGD by a T-cell Derived Cellular Vehicle System in Vivo
Authors: Rutger K. Balvers 1, Sanne K. van den Hengel 2, Hiroaki Wakimoto 3, Rob C. Hoeben 2, Reno Debets 4, Sieger Leenstra 1, Clemens Dirven 1 and Martine L.M. Lamfers 1
Affiliations: 1 Dept of Neurosurgery, Brain Tumor Center, Erasmus MC, Rotterdam, Netherlands; Dr. Molewaterplein 50, Ee2236, 3015GE, Rotterdam, The Netherlands
2 Department of Molecular Cell Biology, LUMC Leiden, The Netherlands
3 Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Massachusetts General Hospital, Boston, USA
4 Laboratory of Experimental Tumor Immunology, Department Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Corresponding author: Martine Lamfers, Department of Neurosurgery, Erasmus MC Rotterdam, firstname.lastname@example.org
Short Title: Carrier cell mediated delivery of Delta24-RGD in invasive GBM
Abstract: Oncolytic adenoviral vectors are a promising alternative for the treatment of glioblastoma. Recent publications have demonstrated the advantages of shielding viral particles within cellular vehicles (CVs), which can be targeted towards the tumor microenvironment. We investigated the feasibility of using a T-cell derived CV system to deliver the oncolytic adenovirus Delta24-RGD to glioblastoma.
The T-cell derived cell line Jurkat was assessed in co-culture with the glioblastoma stem cell line GBM8 for optimal transfer conditions of Delta24-RGD in vitro. The effect of intraparenchymal and tail-vein injections on intratumoral viral distribution and overall survival was addressed in an orthotopic GSC based xenograft model.
Jurkats were demonstrated to facilitate Delta24-RGD amplification and transfer to GSC’s. Delta24-RGD dosing and incubation time were found to influence the migratory ability of Jurkats towards GSC’s. Injection of Delta24-RGD-loaded Jurkats into the brains of GBM8-bearing mice led to Jurkat migration towards the tumor and dispersion of the virus within its core and infiltrative zones. This occurred after injection into the ipsi-lateral hemisphere as well as into the contralateral hemisphere. We found that Jurkat-mediated delivery of Delta24RGD led to inhibition of tumor growth compared to controls, resulting in prolonged survival compared to controls (46 days versus 38 days, p=0.007). However, tail-vein injections failed to demonstrate intraparenchymal Jurkat or viral delivery.
Based on these findings we conclude that T-cell based CV’s are a feasible candidate for Delta24-RGD delivery in glioblastoma, although efficient systemic targeting needs further evaluation.
Keywords: Glioblastoma; Oncolytic; Cellular Vehicles; GSC; Virotherapy; Delta24-RGD
Last update: 6 June 2014